Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs

Strong Cash Position with Runway into Fourth Quarter 2024

Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs

Preclinical Data from HMI-103 Gene Editing Program Utilizing a Unique Mechanism of Action Demonstrated Significantly Increased Potency in PKU Model

Excerpt from the Press Release:

EDFORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today enrollment and site status updates from the pheEDIT Phase 1 gene editing trial with HMI-103 for phenylketonuria (PKU) and the juMPStart Phase 1 gene therapy trial with HMI-203 for Hunter syndrome (MPS II).

The first participant was recently dosed in the pheEDIT trial, with additional participants in screening. Homology expects to provide initial data from the trial mid-year 2023. There are nine active clinical trial sites with more expected to be initiated throughout 2023. The juMPStart trial has five clinical sites in the U.S. and Canada with more expected to be initiated, and initial data is expected in the second half of 2023.

“With a solid financial position, our focus is and will continue to be centered on clinical trial execution,” said Albert Seymour, Ph.D., President and Chief Executive Officer. “HMI-103 and HMI-203 represent differentiated one-time approaches to PKU and MPS II, respectively, designed to address key unmet medical needs.

Click the button below to read the entire Press Release:

Continue Reading The Press Release